Pyrotinib, a pan-ErbB inhibitor which was designed to target HER2 in breast cancer and NSCLC, showed potent binding activity to G719A (Figure 4F), which was observed conferring similar molecular interactions like afatinib, dacomitinib and osimertinib. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.